| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | T10; CD38 |
| Entrez GeneID | 952 |
| clone | 6E12D4A12 |
| WB Predicted band size | 34kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CD38 expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇关于CD38抗体的代表性文献摘要(信息已简化整理)：
1. **文献名称**：Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
**作者**：Mateos MV 等(2018)
**摘要**：该III期临床试验证明，在复发/难治性多发性骨髓瘤患者中，CD38单抗达雷妥尤单抗联合硼替佐米和地塞米松(D-Vd方案)较对照组显著延长无进展生存期(PFS)，总体缓解率提高至85%，且安全性可控。
2. **文献名称**：CD38 antibodies in multiple myeloma: mechanisms of action and clinical experience
**作者**：van de Donk NWCJ 等(2021)
**摘要**：综述了CD38抗体(如达雷妥尤单抗、isatuximab)的作用机制，包括抗体依赖性细胞毒性(ADCC)、补体依赖细胞毒性(CDC)及免疫调节效应，并总结其在不同治疗线次中的临床数据及耐药管理策略。
3. **文献名称**：Isatuximab plus pomalidomide and dexamethasone in relapsed myeloma
**作者**：Attal M 等(2020)
**摘要**：ICARIA-MM研究显示，CD38单抗isatuximab联合泊马度胺和地塞米松显著改善复发/难治性多发性骨髓瘤患者的中位PFS(11.5 vs 6.5个月)，且对达雷妥尤单抗经治患者仍显示临床活性。
注：以上文献均发表于《新英格兰医学杂志》《柳叶刀·肿瘤学》等权威期刊，聚焦CD38抗体在血液肿瘤治疗中的转化应用。
CD38 is a transmembrane glycoprotein expressed on various immune cells, including plasma cells, natural killer (NK) cells, and subsets of T and B cells. It functions as both an enzyme (cyclic ADP-ribose hydrolase) and a receptor, playing roles in cell adhesion, signaling, and calcium homeostasis. Its overexpression on malignant plasma cells in multiple myeloma (MM) and other hematologic malignancies makes it a therapeutic target.
CD38-targeting monoclonal antibodies, such as daratumumab and isatuximab, have revolutionized MM treatment. These antibodies bind to CD38. triggering tumor cell death through multiple mechanisms: antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), direct apoptosis induction, and immune modulation by depleting immunosuppressive CD38-positive regulatory cells. Daratumumab, the first FDA-approved anti-CD38 antibody (2015), has shown significant efficacy in relapsed/refractory and newly diagnosed MM, often combined with standard therapies. Isatuximab, approved in 2020. offers an alternative with a distinct epitope binding profile.
Beyond MM, CD38 antibodies are explored in amyloidosis, autoimmune disorders, and solid tumors. Challenges include managing infusion-related reactions and CD38 expression downregulation post-treatment. Ongoing research focuses on optimizing combination regimens, reducing toxicity, and expanding applications, reinforcing CD38’s role as a pivotal target in immunotherapy.
×
